Related Experiment Videos
Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous
Insights
Iron chelation therapy with desferrioxamine (DFO) in children with thalassemia major shows delayed effectiveness. Continuous subcutaneous DFO requires over a year to reduce iron overload, unlike intramuscular DFO which shows increasing ferritin levels.
Area of Science:
- Pediatrics
- Hematology
- Pharmacology
Background:
- Thalassemia major necessitates regular blood transfusions, leading to iron overload.
- Iron overload poses significant health risks in patients with thalassemia major.
- Desferrioxamine (DFO) is a primary iron chelation therapy.
Purpose of the Study:
- To evaluate the time-dependent efficacy of desferrioxamine (DFO) in reducing serum ferritin levels in children with thalassemia major.
- To compare the effectiveness of intramuscular DFO versus continuous subcutaneous DFO infusion.
Main Methods:
- A longitudinal study tracking serum ferritin concentrations in two groups of children with thalassemia major.
- Group 1: 19 children treated with intramuscular DFO (20 mg/kg/day for 20 days/month).
- Group 2: 12 children treated with continuous subcutaneous DFO (≥20 mg/kg/day for 6 days/week).
Main Results:
- Intramuscular DFO showed a progressive increase in serum ferritin over 739 days (8.53 ng/ml/day).
- Continuous subcutaneous DFO resulted in a lower daily ferritin increase (4.77 ng/ml/day).
- Serum ferritin levels decreased only after 360 days of subcutaneous DFO treatment, despite ongoing iron contribution from transfusions.
Conclusions:
- Continuous subcutaneous DFO demonstrates a delayed but eventual reduction in iron overload.
- More than one year of subcutaneous DFO treatment is needed to achieve a decrease in body iron stores.
- Treatment modality and duration significantly impact the effectiveness of iron chelation therapy in thalassemia major.
Abstract:
A longitudinal study has been conducted on serum ferritin concentrations in children with thalassemia major treated with desferrioxamine (DFO), both intramuscularly and by continuous subcutaneous infusion, in order to evaluate the time interval after which iron chelation becomes effective. In a first group of 19 children, treated intramuscularly with DFO at a dose of 20 mg/kg for 20 days a month, ferritin levels were followed for 739 days and a progressive increase with a significant linear correlation with time was seen. The daily increase was calculated to be 8.53 +/- 1.95 ng/ml. In the second group of 12 children treated with DFO by continuous subcutaneous infusion (greater than or equal to 20 mg/kg/day for 6 days a week), the increase in ferritin was markedly lower, the mean daily value being 4.77 +/- 3.30 ng/ml. Only after the first 360 days of treatment did the serum ferritin decrease, by 1.95 +/- 3.32 ng/ml/day, in spite of a mean daily iron contribution from blood transfusions of 7.09 +/- 2.69 mg/day. These changes in serum ferritin led us to conclude that one can only expect to obtain a decrease in the body's iron overload after more than a year of treatment with subcutaneous DFO.